Filgrastim(rh-G-CSF)

タイトルまたは説明

Product Description
[Chemical Name]

Recombinant human granulocyte colony- stimulating factor injection

[COMPOSITION]

Recombinant human granulocyte colony- stimulating factor.

[Character]

This product is colorless sterile solution

[ROUTE OF ADMINISTRATION]

This product should be administered through subcutaneous and intravenous way.

[INDICATIONS]

Patients with severe granulocytopenia resulting from chemotherapy
Patients receiving myosuppressed drugs, especially some severe and bone marrow depriving chemicals , if put in use WHITE-C can prevent and lighten the degree of granulocytopenia and shorten duration of granulocytopenia as well as hasten the regain of the granulocytes , consequently reduce the risk of combined infection.

[Dosage and administration]

Subcutaneously or intravenously administer the drug once a day *4~*8hs after the chemotherapy administration and dosage of should take chemotherapy and degree of granulocytopenia into account.
For patients with intensive chemotherapy or with obvious granulocytopenia symptoms should administer WHITE-C for 7 consecutive days at the dose of *5ug/kg until recovering to ***0/mm3
If chemical drugs used are small , patients may be administered WHITE-C at the dose of 1.*5ug/kg until the steady regain in safe range
If the quantity of granulocyte declined obviously after chemotherapy (say <***0/mm3), patients should receive the drug at the dose of 5ug/kg till granulocytes increase more than ***0/mm3 , if it is stable, stopping the drug should be taken into account.
Product Feature
rhG-CSF (Recombinant Human Granulocyte/Macrophage Colony-stimulating Factor Injection)

Reduce serious infection that may threaten life.

Improve success rate of transplant

Reduce the use of antibiotics and therefore medical cost.

Guarantee the effect of chemotherapy and improve the survival rate of patients

[Clinical indications of White-C]

It can stimulate bone marrow to produce granulocytes and neutrophils. It is mainly used in the treatment of neutropenia and granulocytopenia induced by

(1) Tumor treatment

(2) AIDS treatment

(3) Leukemia treatment

(4) Aplastic anemia

(5) Bone marrow transplant

(6) MDS

(8) Liver and kidney transplant
[Strength]

*5ug/vial or pfs, **0ug/vial or pfs, **0ug/vial or pfs, API